Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System.
about
Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and MarrowFLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission.Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.Routine blood examinations combined with morphological analysis for the diagnosis of myelodysplastic/myeloproliferative neoplasms.Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groupsI walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.Laboratory diagnosis of chronic myelomonocytic leukemia and progression to acute leukemia in association with chronic lymphocytic leukemia: morphological features and immunophenotypic profile.Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study.Characteristics and outcome in patients with non-specific symptoms and signs of cancer referred to a fast track cancer patient pathway; a retrospective cohort study.Models of Prognostication in Chronic Myelomonocytic Leukemia.Therapy for Chronic Myelomonocytic Leukemia in a New Era.Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.Immunophenotypes of Chronic Myelomonocytic Leukemia (CMML) Subtypes by Flow Cytometry: A Comparison of CMML-1 vs CMML-2, Myeloproliferative vs Dysplastic, De Novo vs Therapy-Related, and CMML-Specific Cytogenetic Risk Subtypes.Activity of azacitidine in chronic myelomonocytic leukemia.Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML
P2860
Q33583033-B3B51079-7D9E-41E5-BA99-ACACAEB05CA7Q35162458-748033B9-BB43-4A02-A668-02437A2B77D7Q35714782-BE0BCA62-1565-4F85-ACDD-A5BF4F4120D0Q36183556-98060A33-2353-42DE-BC30-F8E94C79AE5DQ36467544-F4CCC250-4BC8-40AA-9F1E-34A21D9B4898Q36967029-0AA1C890-EFB2-4346-9D84-4E0FE3094B2AQ37164061-CBDA8DFF-AD14-45B5-995E-DFED43F3A028Q37189322-A4FD3935-AF4D-4A4D-B291-7EBEC28C9CFDQ37407367-C8DA5034-EB18-4F82-A672-04F7FE5F9384Q38012085-709BB4D2-17F9-44FD-AE45-F6E829D1E315Q38130476-D4D3C0B4-5B56-44F3-BE3A-764C3FD9E971Q38134374-907CEF8B-5684-46EC-A496-2B451816798AQ38246598-CD8B7B14-0F04-45BB-8E6A-D5F4B5776798Q41858668-3993BE74-52B6-4A1A-A6FD-46F6F2C86105Q42638915-4B8995C6-6000-4681-8B42-2A2B7AD47197Q45358400-6BE992D6-4682-4A2A-B4CB-965FFB2FAB27Q47163996-FD879D57-4078-4EA0-A791-B6786BD77CF5Q47731555-0B3869AF-B5B4-4268-B9DD-E2486D22F6CDQ47853133-7BB996CD-70E6-4BAE-8554-7ABED80C72E9Q48137636-54BE01CB-4B38-4F5C-883F-BE6C94F13D0BQ53066596-1A608051-4A6E-40BE-86C2-E7464D94978CQ53152113-562514C0-162A-491A-A012-8D08508222DCQ58733645-B0813567-53DD-47D4-8C27-86577DCB1DAF
P2860
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Prognostic factors and risk as ...... son Prognostic Scoring System.
@en
Prognostic factors and risk as ...... son Prognostic Scoring System.
@nl
type
label
Prognostic factors and risk as ...... son Prognostic Scoring System.
@en
Prognostic factors and risk as ...... son Prognostic Scoring System.
@nl
prefLabel
Prognostic factors and risk as ...... son Prognostic Scoring System.
@en
Prognostic factors and risk as ...... son Prognostic Scoring System.
@nl
P2093
P2860
P50
P1433
P1476
Prognostic factors and risk as ...... son Prognostic Scoring System.
@en
P2093
Francesco Onida
Jaroslav Jelinek
Miloslav Beran
P2860
P304
P356
10.1080/10428190701216386
P577
2007-06-01T00:00:00Z